Biohit Oyj B Asset Resilience Ratio
Biohit Oyj B asset resilience ratio. Biohit Oyj B (BIOBV) has an Asset Resilience Ratio of 24.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Biohit Oyj B (BIOBV) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biohit Oyj B (2004–2025)
Asset resilience ratio of Biohit Oyj B from 2004 to 2025. This chart shows how Biohit Oyj B's Asset Resilience Ratio has changed over time. See Biohit Oyj B free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Biohit Oyj B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see BIOBV asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.50 Million | 17.68% |
| Short-term Investments | €1.30 Million | 6.57% |
| Total Liquid Assets | €4.80 Million | 24.24% |
Asset Resilience Insights
- Good Liquidity Position: Biohit Oyj B maintains a healthy 24.24% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Biohit Oyj B Industry Peers by Asset Resilience Ratio
Compare Biohit Oyj B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
VIROMED MEDICAL NA O.N.
XETRA:VME |
Medical Devices | 0.03% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 14.18% |
|
Epitomee Medical Ltd
TA:EPIT |
Medical Devices | 0.24% |
|
Impedimed Ltd
AU:IPD |
Medical Devices | 46.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
Biohit Oyj B Asset Resilience Ratio by Year (2004–2025)
Biohit Oyj B asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for Biohit Oyj B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 24.24% | €4.80 Million ≈ $5.61 Million |
€19.80 Million ≈ $23.15 Million |
-19.04pp |
| 2024-12-31 | 43.28% | €6.71 Million ≈ $7.84 Million |
€15.50 Million ≈ $18.12 Million |
-9.46pp |
| 2023-12-31 | 52.74% | €6.81 Million ≈ $7.97 Million |
€12.92 Million ≈ $15.10 Million |
-3.79pp |
| 2022-12-31 | 56.53% | €6.23 Million ≈ $7.28 Million |
€11.02 Million ≈ $12.88 Million |
-0.84pp |
| 2021-12-31 | 57.37% | €5.51 Million ≈ $6.45 Million |
€9.61 Million ≈ $11.24 Million |
+0.96pp |
| 2020-12-31 | 56.41% | €6.08 Million ≈ $7.11 Million |
€10.78 Million ≈ $12.60 Million |
+10.38pp |
| 2019-12-31 | 46.03% | €8.00 Million ≈ $9.35 Million |
€17.37 Million ≈ $20.31 Million |
+1.29pp |
| 2018-12-31 | 44.74% | €8.00 Million ≈ $9.36 Million |
€17.89 Million ≈ $20.91 Million |
+5.71pp |
| 2017-12-31 | 39.03% | €7.38 Million ≈ $8.62 Million |
€18.89 Million ≈ $22.09 Million |
-15.89pp |
| 2016-12-31 | 54.92% | €7.13 Million ≈ $8.34 Million |
€12.99 Million ≈ $15.19 Million |
-0.65pp |
| 2015-12-31 | 55.58% | €6.52 Million ≈ $7.62 Million |
€11.73 Million ≈ $13.71 Million |
-12.04pp |
| 2014-12-31 | 67.62% | €9.81 Million ≈ $11.47 Million |
€14.51 Million ≈ $16.96 Million |
+13.77pp |
| 2013-12-31 | 53.84% | €15.24 Million ≈ $17.82 Million |
€28.30 Million ≈ $33.09 Million |
-21.73pp |
| 2012-12-31 | 75.57% | €30.23 Million ≈ $35.35 Million |
€40.01 Million ≈ $46.77 Million |
+61.58pp |
| 2011-12-31 | 13.99% | €10.00 Million ≈ $11.69 Million |
€71.47 Million ≈ $83.56 Million |
+12.29pp |
| 2010-12-31 | 1.70% | €500.00K ≈ $584.55K |
€29.38 Million ≈ $34.35 Million |
+0.24pp |
| 2009-12-31 | 1.46% | €400.00K ≈ $467.64K |
€27.40 Million ≈ $32.03 Million |
-0.31pp |
| 2008-12-31 | 1.77% | €480.00K ≈ $561.17K |
€27.11 Million ≈ $31.69 Million |
-1.61pp |
| 2007-12-31 | 3.38% | €923.00K ≈ $1.08 Million |
€27.34 Million ≈ $31.96 Million |
+0.24pp |
| 2006-12-31 | 3.13% | €856.00K ≈ $1.00 Million |
€27.32 Million ≈ $31.94 Million |
-5.48pp |
| 2005-12-31 | 8.62% | €2.40 Million ≈ $2.81 Million |
€27.85 Million ≈ $32.56 Million |
+8.63pp |
| 2004-12-31 | -0.02% | €-4.00K ≈ $-4.68K |
€22.76 Million ≈ $26.61 Million |
-- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more